BIBF 1120 nintedanib Catalent

Glavne informacije

  • Zaščiteno ime:
  • BIBF 1120 nintedanib Catalent 150 mg mehke želatinaste kapsule
  • Farmacevtska oblika:
  • kapsula, mehka
  • Pot uporabe:
  • Način uporabe nedoločen
  • Enote v paketu:
  • 60 kapsul v eni škatli
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • BIBF 1120 nintedanib Catalent 150 mg mehke želatinaste kapsule
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Zaviralci proteinskih kinaz

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Zdravilo z začasnim dovoljenjem za vnos/uvoz za posamično zdravl
  • Datum dovoljenje:
  • 28-02-2014
  • Zadnja posodobitev:
  • 19-01-2018

30-7-2018

Ofev (Boehringer Ingelheim International GmbH)

Ofev (Boehringer Ingelheim International GmbH)

Ofev (Active substance: Nintedanib) - PSUSA - Modification - Commission Decision (2018)5115 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10319/201710

Europe -DG Health and Food Safety

25-7-2018

Vargatef (Boehringer Ingelheim International GmbH)

Vargatef (Boehringer Ingelheim International GmbH)

Vargatef (Active substance: nintedanib) - PSUSA - Modification - Commission Decision (2018)4976 of Wed, 25 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2569/PSUSA/10318/201710

Europe -DG Health and Food Safety

6-6-2018

Prolia (Amgen Europe B.V.)

Prolia (Amgen Europe B.V.)

Prolia (Active substance: denosumab) - Centralised - 2-Monthly update - Commission Decision (2018) 3685 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1120/II/68

Europe -DG Health and Food Safety